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Consanguineous populations of the Arabian Peninsula, which has seen an uncontrolled rise in type 
2 diabetes incidence, are underrepresented in global studies on diabetes genetics. We performed a 
genome-wide association study on the quantitative trait of fasting plasma glucose (FPG) in unrelated 
Arab individuals from Kuwait (discovery-cohort:n = 1,353; replication-cohort:n = 1,196). Genome-wide 
genotyping in discovery phase was performed for 632,375 markers from Illumina HumanOmniExpress 
Beadchip; and top-associating markers were replicated using candidate genotyping. Genetic models 
based on additive and recessive transmission modes were used in statistical tests for associations 
in discovery phase, replication phase, and meta-analysis that combines data from both the 
phases. A genome-wide significant association with high FPG was found at rs1002487 (RPS6KA1) 
(p-discovery = 1.64E-08, p-replication = 3.71E-04, p-combined = 5.72E-11; β-discovery = 8.315; 
β-replication = 3.442; β-combined = 6.551). Further, three suggestive associations (p-values < 8.2E-06) 
with high FPG were observed at rs487321 (CADPS), rs707927 (VARS and 2Kb upstream of VWA7), and 
rs12600570 (DHX58); the first two markers reached genome-wide significance in the combined analysis 
(p-combined = 1.83E-12 and 3.07E-09, respectively). Significant interactions of diabetes traits (serum 
triglycerides, FPG, and glycated hemoglobin) with homeostatic model assessment of insulin resistance 
were identified for genotypes heterozygous or homozygous for the risk allele. Literature reports 
support the involvement of these gene loci in type 2 diabetes etiology.
A large number of genome-wide association studies have been conducted in various populations (mostly on 
Europeans, Americans, and East Asians), resulting in the identification of more than 100 loci conferring suscepti-
bility to type 2 diabetes mellitus1–4. Meta-analysis and genotype imputations from diverse ethnic populations help 
identify novel markers and causal loci. However, despite the observed high prevalence of type 2 diabetes in Arab 
countries5,6, their populations were not included in global studies.
The Arabian Peninsula is at the nexus of Africa, Europe, and Asia; and has been assumed to be an early human 
migration route out of Africa. Consanguineous marriage (especially among first or second cousins) is an estab-
lished practice among the Arabian Peninsula population. Consanguinity results in increased homozygosity, and 
accumulation of deleterious recessive alleles in the gene pool, creating the potential for certain variants to become 
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more common in these endogamous population groups; these features can influence the etiology of complex 
disorders7. Therefore, elucidating novel risk variants is realistically possible in this population.
The Kuwaiti population consists of settlers from Saudi Arabia, Iran, and other neighboring countries within 
the Peninsula. Such settlement and subsequent admixture shaped the genetics of the Kuwaiti population. Our 
earlier work showed that the Kuwaiti population is heterogeneous, but structured, and carries a large burden of 
homozygosity8. Kuwaiti population groups practice consanguineous marriage; a survey in Kuwait reported that 
the rate of consanguineous marriages was as high as 54% and the average inbreeding coefficient was 0.02199. 
These practices indicate that groups live in isolation by community leading to genetic isolates in extended families 
and Bedouin tribes10. Using these small population isolates can reduce the complexity of polygenic disorders by 
reducing the number of loci involved in disorder etiology11. In the present study, we performed a genome-wide 
association study (GWAS) on native Arab individuals from Kuwait to delineate novel risk variants for fasting 
plasma glucose (FPG). We further examined associations between glucose-related traits and insulin resistance 
traits in individuals with genotypes, heterozygous or homozygous, for the risk allele at the identified risk variants.
Results
Marker and sample sets. Quality control analyses resulted in a marker set of 632,375 SNPs (reduced down 
from 730,525), discovery cohort of 1,353 samples (reduced down from 1913), and replication cohort of 1,176 
samples. The discovery cohort was estimated to have 80% power to detect associations (under additive and reces-
sive models) with a genetic effect that explained 0.6% of the variance in the trait. The acceptable effect sizes at dif-
ferent allele frequencies for associations with FPG (in discovery phase) are presented in Supplementary Table S1.
Characteristics of study participants. The study cohorts were described in our previous reports12,13. 
Participants (comprising almost equal proportions of men and women) were largely middle-aged (mean age in 
discovery cohort, 46.8 ± 13.8 years) (Table 1) and were largely obese (mean body mass index, 32.4 ± 7.4 kg/m2) 
with high waist circumference (102.21 ± 16.35 cm). The proportions of participants afflicted with type 2 diabetes 
from the discovery and replication cohorts were 45% and 39%, respectively. A total of 216 of the participants 
from the discovery cohort were being administered glucose-lowering medication. Mean FPG values in the dis-
covery and replication cohorts were 7.3 ± 3.57 and 5.86 ± 2.27 mmol/L, respectively, and were in the range of the 
ADA-defined threshold of 5.5–6.9 mmol/L for diagnosing impaired fasting glucose. Mean HbA1c values in the 
discovery and replication cohorts were 7.1 ± 2.1%, and 6.00 ± 1.4%, respectively. While FPG measurements were 
available for all participants of the discovery cohort, HbA1c values were available for only 750; hence, markers 
associated with only HbA1c were excluded from further analyses.
Scatterplots presenting the first three principal components derived from a merged data set of the discovery 
cohort and representative populations from the Human Genome Diversity Project (HGDP) are presented in 
Supplementary Figure S1; the scatterplots depict three genetic substructures and agree with the PCA plot (repro-
duced in Supplementary Figure S2) that we derived earlier using a set of native Kuwaiti individuals whose Arab 
ethnicity was confirmed through surname lineage analysis8.
Associations observed in discovery and replication phases. Upon examining the association test 
results from discovery phase for at least nominal p-values of <1.0E-05 and acceptable beta values, we short-listed 
22 markers (21 associated with FPG and 1 with both FPG and HbA1c) to carry forward to the replication phase; 
Table 2 presents their quality assessment values in the replication phase. Intensity maps displaying the qual-
ity of the three called genotypes at these markers are presented in Supplementary Figure S3. Quantile–quantile 
plots depicting the expected and observed −log10(p-values) for association of the markers with FPG are pre-
sented in Fig. 1. Genomic-control inflation factors for FPG were (λ = 1.047, recessive model; λ = 1.077, additive 
model) in tests with regular corrections and (λ = 1.031, recessive model; λ = 1.069, additive model) in tests cor-
rected further for glucose-lowering medication. Similar values were obtained for HbA1c. These values at close 
to 1.0 and differing only over a small range of 1.03–1.08 do not necessitate correcting association statistics for 
genomic-control inflation. Manhattan plots depicting the −log10(p-values) from the GWAS for the FPG trait 
are presented in Supplementary Figure S4. Four markers (i.e., rs12488539, rs6762914, rs1199028, rs7329697) 
failed the SNP quality assessment tests for Hardy–Weinberg equilibrium quality control (HWE >10−6); and 
none failed the test for allele frequency consistency (between discovery and replication phases). Table S2 lists, 
for all 22 markers, results of association tests (with regular corrections and additionally corrected for diabetes 
medication) from the discovery and replication phases as well as meta-analysis of the combined results from 
both phases. The analysis produced a short-list of four associations for FPG that showed significant p-values 
in discovery phase (one at a genome-wide significant p-value of <1.8E-08 and three at nominal p-values of 
<1.0E-05) and that passed the p-value threshold in the replication phase; three of them reached genome-wide 
significance in the meta-analysis that combines and jointly analyze the data from both the discovery and rep-
lication phases (Table 3). Such markers were rs1002487/[intronic from RPS6KA1] (p-discovery = 1.64E-08, 
p-replication = 3.71E-04, p-combined = 5.72E-11), rs487321/[intronic from CADPS] (p-discovery = 1.53E-
07, p-replication = 2.25E-06, p-combined = 1.83E-12), rs707927/[intronic from VARS and 2 Kb upstream of 
VWA7] (p-discovery = 8.24E-06, p-replication = 8.25E-05, p-combined = 3.07E-09), and rs12600570/[intronic 
from DHX58] (p-discovery = 7.49E-06, p-replication = 4.67E-03, p-combined = 2.72E-07); the former two were 
recessive and the latter were additive markers. Further corrections for glucose-lowering medication retained 
significant p-values and effect sizes. Upon performing inverse normal transformation on the FPG traits, p-values 
for the association of rs707927 improved to 1.26E-07 (effect size = 0.33). The RPS6KA1 marker was also asso-
ciated with HbA1c at close to the p-value threshold for genome-wide significance (p-discovery = 4.91E-08; 
p-replication = 2.71E-03; p-combined = 7.27E-09).
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Considering the diabetes and obesity status of the participants as covariates for adjustments 
on the association models. 45% of participants in the discovery phase, and 38% of participants in the 
replication phase, respectively, were diagnosed for diabetes (see Table 1). It is further the case that obesity seems 
to be a major driver of diabetes in the whole sample – 59% of participants in the discovery phase and 46% of 
participants in the replication phase, respectively, were obese. Thus, it is important to perform corrections for the 
association tests for diabetes and obesity status along with corrections for diabetes and lipid lowering medications 
(lipid lowering medications can influence FPG levels). Upon performing the corrections for these 4 covariates 
along with the regular corrections, it was found that the p-values remained significant at p-combined = 1.38E-10 
(for RPS6KA1 marker), 1.88E-13 (for CADPS marker), 1.23E-08 (for VARS marker) and 2.78E-05 (for DHX58 
marker) (Table 4).
Sensitivity analysis. A concern arises as to whether the FPG values measured in individuals receiving 
glucose-lowering medication represent “naturally” observed values in the population. We addressed this concern 
by way of performing a sensitivity analysis to add a value of 2.5 mmol/L to the FPG values of the participants 
taking diabetes medication and then performing the association tests; the value of 2.5 mmol/L is an average effect 
size (p-value < 0.001) that we observed in an in-house clinical database of diabetic patients visiting clinics in our 
institute. The results of association tests with the preadjusted FPG values for the four identified associations (with 
corrections for regular confounders and BMI) are presented in Table 5. The associations retained the p-values.
Assessing the identified associations in sub-cohorts of entirely diabetic or of entirely 
non-diabetic participants. The discovery and replication cohorts used in this study included both diabetic 
patients and healthy participants; as mentioned above, the identified associations retained significance when the 
models were adjusted for the covariate of diabetes status. It is often the case that quantitative trait associations 
are done on entirely non-diabetic participants or on entirely diabetic patients (which gives a higher chance of 
translating the findings to clinical utility). We distributed the discovery cohort (n = 1353) and replication cohort 
(n = 1176) onto four sub-cohorts: (i) Discovery_diabetic (n = 605); (ii) Discovery_non-diabetic (n = 748); (iii) 
Replication_diabetic (n = 452); and (iv) Replication_non-diabetic (n = 724). We performed association tests with 
each of the four sub-cohorts followed by three meta-analysis (Meta_diabetic: combining results from Discovery_
diabetic and Replication_diabetic), (Meta_non-diabetic: combining results from Discovery_non-diabetic and 
Replication_non-diabetic) and (Meta_all: combining results from all the four sub-cohorts). With regular correc-
tions performed on the association tests, the effect sizes and p-values remained significant in the Meta_diabetic 
Discovery Cohort 
(mean ± SD)
Replication Cohort 
(mean ± SD)
p-values for differences between 
Discovery and Replication cohorts
Sex, Male:Female 667:686 673:503 7.96E-05
Age, years ± SD 47 ± 13.8 47 ± 10.7 0.97
Weight, Kg ± SD 88.5 ± 21.1 92.4 ± 17 3.62E-06
Height, cm ± SD 165 ± 9.6 166.5 ± 8.9 0.006
BMI, Kg/m2 ± SD 32.4 ± 7.4 31.2 ± 5.7 6.15E-06
WC, cm ± SD 102.2 ± 16.4 100.5 ± 12.1 0.003
LDL, mmol/L ± SD 3.1 ± 0.97 3.4 ± 0.9 <2.2E-16
HDL, mmol/L ± SD 1.1 ± 0.4 1.1 ± 0.3 0.82
TC, mmol/L ± SD 4.9 ± 1.1 5.2 ± 1.0 7.77E-12
TG, mmol/L ± SD 1.7 ± 1.2 1.6 ± 1.0 0.002
HbA1c, mmol/L ± SD 7.1 ± 2.1 6.0 ± 1.4 <2.2E-16
FPG, mmol/L ± SD 7.3 ± 3.6 5.9 ± 2.3 <2.2E-16
SBP, mmHg ± SD 128 ± 17.5 129.1 ± 16.7 0.06
DBP, mmHg ± SD 77.9 ± 10.6 78.7 ± 11.1 0.035
Proportion of the participants that are obese@ 
(BMI ≥ 30 Kg/m2) 59.3% 45.5% 7.43E-05
Proportion of the participants that are diabetic 44.7% 38.4% 0.002
Proportion of the participants that are hypertensive 44.9% 35.7% 3.61E-06
Proportion of the participants that consume lipid 
lowering medication 9.8% 0.3% <2.2E-16
Proportion of the participants that consume glucose 
lowering medication 16.0% 4.6% <2.2E-16
Proportion of the participants that consume blood 
pressure medication 11.9% 7.2% 0.0
Table 1. Demographic characteristics of the study participants. Abbreviations: WC, waist circumference; 
TC, total cholesterol; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; SD, standard deviation. @The distribution of the participants onto 
normal weight (BMI 20 to <25): overweight (BMI 25 to <30): obese (BMI 30 to <40): morbid obese 
(BMI ≥ = 40) = 222:328:597:206 in the discovery cohort; and 93:442:559:82 in the replication cohort.
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analysis (Table 6) for the markers from the RPS6KA1 (β = 6.01; p = 1.84E-09), CADPS (β = 5.13; p = 2.86E-07) 
and VARS (β = 4.68; p = 2.83E-06) genes and in the Meta_non-diabetic analysis for the marker from the DHX58 
gene (β = 3.81; p = 1.30E-04); considering that the sizes of the sub-cohorts reduced considerably, these values 
can be considered significant. In addition, the p-values for Meta_all analysis (β = 5.46; p = 4.82E-08) remained 
significant for the VARS marker.
Examining the NHGRI-EBI GWAS catalog for previous association reports on the identified risk 
variants. While none of the identified risk variants was associated with any trait in previous GWAS, the gene 
loci were often associated with traits related to diabetes: RPS6KA1 with glucose homeostasis traits14, sporadic 
amyotrophic lateral sclerosis15, and the symptom of rosacea16; DHX58 with coronary artery disease (CAD)17; 
VARS with blood plasma proteome18, autism spectrum disorder (ASD)19, and inflammatory bowel disease 
(IBD)20; VWA7 with blood protein levels18, ASD19, and IBD20; and CADPS with treatment interaction of sulfony-
lurea (a glucose-lowering drug)21, heart failure-related metabolite levels22, and obsessive-compulsive symptoms23.
LD markers and regional associations. Figure 2 presents regional association plots for regions of 500 Kb 
centered at the identified four risk variants; these regions (other than for the CADPS marker) were gene-dense. 
The (VARS, VWA7) and DHX58 markers had 21 and 7 LD partners (r2 > 0.59), respectively. Several LD part-
ners were associated with FPG at suggestive p-values of <1E-04 (Supplementary Table S3). Examination of the 
NHGRI-EBI GWAS catalog listed the following two LD partners (that associated in our study population at a 
p-value of E-05): (i) rs2074158-T (missense) (LD [r2 = 0.56] partner of DHX58 risk variant) associated with 
CAD (p-value = 2.0E-10) in UK BioBank populations17; and (ii) rs9469054-A (intronic) (LD [r2 = 0.85] partner 
of [VARS, VWA7] risk variant) associated with monocyte count (p-value = 1.0E-20)24; shared genetic pathways 
linking blood cell counts with complex pathologies (including CAD) have been reported24.
ROH segments overlaying the identified risk variants. All of the four reported risk variants were in 
ROH (Table 7). The observed maximum values for of the ROH region lengths (mean ± SD of the ROH groups) 
were 8 Mb (RPS6KA1 marker), 15.5 Mb (CADPS), 9.9 Mb (VARS, VWA7), and 6.96 Mb (DHX58). The two reces-
sive risk variants from RPS6KA1 and CADPS were in “known” ROH segments, while the two additive markers 
from (VARS, VWA7) and DHX58 were in “novel” segments. However, LD partners of the additive risk variants 
lay in “known” ROH segments – one such marker (i.e., rs2074158/DHX58) in LD with the DHX58 risk variant is 
listed in the GWAS catalog as being associated with CAD (see Table 7). Presence of the identified ROH segments 
(to which the associated variant overlaps) is found more often in sub-cohort of diabetic participants than in 
Chr SNP
Ref/Alt Allele, 
Traitmodel
Discovery Replication
EAF Genotype O(HET) E(HET) p-value EAF Genotype O(HET) E(HET) p-value
1 rs1002487 T/C, FPG, HbA1C# 0.0594 5/151/1196 0.1117 0.112 0.8088 0.05119 5/110/1057 0.09386 0.0972 0.2241
2 rs4143782 C/T, FPG@ 0.1812 47/396/909 0.1117 0.112 0.8088 0.1702 35/330/811 0.2803 0.2824 0.7791
3 rs12488539& G/T, FPG@ 0.2914 110/565/672 0.2929 0.2967 0.6466 0.2047 0/481/695 0.4094 0.3256 1.26E-16&
3 rs6762914& T/C, FPG@ 0.3197 135/595/623 0.4195 0.413 0.5978 0.205 0/482/694 0.4101 0.326 5.5E-11&
3 rs487321 A/G, FPG# 0.0821 8/206/1138 0.1524 0.1507 0.8567 0.0564 7/118/1048 0.1004 0.1066 0.0414
5 rs17065898 T/C, FPG@ 0.1949 55/413/874 0.4398 0.435 0.708 0.0959 14/201/961 0.1709 0.1756 0.292
6 rs707927 A/G, FPG@ 0.1062 15/257/1079 0.3077 0.3138 0.4864 0.1014 22/193/958 0.1649 0.1823 0.0121
6 rs1145784 G/A, FPG# 0.0983 12/242/1099 0.1902 0.1899 1 0.09617 16/194/965 0.1651 0.1738 0.09178
7 rs2522219 A/G, FPG# 0.04922 4/125/1222 0.1789 0.1773 0.8781 0.03712 0/87/1085 0.07423 0.0715 0.4022
8 rs1199028& A/C, FPG# 0.1478 28/342/976 0.09252 0.0936 0.5619 0.1943 58/238/615 0.2613 0.3131 2.3E-06&
8 rs2599723 G/A, FPG# 0.0518 4/132/1214 0.09778 0.09833 0.7794 0.0627 7/134/1032 0.1144 0.1176 0.262
10 rs3812689 G/A, FPG# 0.06135 10/146/1197 0.2541 0.252 0.8291 0.0664 6/144/1024 0.1227 0.1241 0.6371
11 rs918988 T/C, FPG@ 0.4217 256/629/468 0.4649 0.4877 0.0842 0.3236 165/598/671 0.417 0.4377 0.0855
11 rs1151501 A/G, FPG@ 0.1116 16/270/1067 0.1996 0.1983 0.8917 0.0889 15/179/979 0.1527 0.162 0.0339
12 rs11179003 C/T, FPG# 0.0565 9/135/1209 0.0997 0.1067 0.0342 0.03731 3/101/1330 0.0704 0.0718 0.4451
13 rs7329697& T/C, FPG# 0.09904 13/242/1098 0.1789 0.1785 1 0.113 41/184/951 0.1565 0.2005 5.2E-09&
13 rs4646213 G/A, FPG# 0.09202 12/225/1116 0.1663 0.1671 0.8702 0.09327 11/197/966 0.1678 0.1691 0.7305
14 rs3784240 G/A, FPG# 0.06615 11/157/1185 0.116 0.1235 0.04233 0.05641 6/120/1044 0.1026 0.1065 0.2609
15 rs1256826 A/G, FPG@ 0.1135 20/267/1066 0.1973 0.2012 0.498 0.1213 22/240/909 0.205 0.2131 0.2151
17 rs930514 A/G, FPG@ 0.4933 331/671/349 0.4967 0.4999 0.8277 0.4801 271/581/321 0.4944 0.4992 0.7114
17 rs12600570 C/T, FPG@ 0.1482 34/333/986 0.2461 0.2525 0.3341 0.1444 28/358/1048 0.2497 0.247 0.7491
18 rs9959376 C/T, FPG# 0.09726 20/223/1109 0.1649 0.1756 0.02979 0.0966 18/191/967 0.1625 0.1745 0.0142
Table 2. SNP quality assessment statistics for the 22 markers assessed in the replication phase. #Association 
with the trait was observed under the genetic model based on recessive mode of inheritance; @association 
with the trait was observed under the genetic model based on additive mode of inheritance. &The markers 
(rs12488539, rs6762914, rs1199028 and rs7329697) fail in HWE test in replication phase.
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sub-cohort of non-diabetic participants, though the size of the former sub-cohort (n = 605) is smaller than that of 
the latter sub-cohort (n = 748); however, the differences are not seen statistically significant.
Gene expression regulation by the identified risk variants. Examination of Genotype-Tissue 
Expression (GTeX) data (https://www.gtexportal.org) revealed that all four risk variants regulate the expression of 
their own or other genes. The RPS6KA1 marker regulates the DHDDS gene in the heart’s left ventricle; the CADPS 
marker regulates itself in the artery-tibial and adipose-subcutaneous tissues; the (VARS, VWA7) marker regulates 
a number of genes [LY6G5B (artery-tibial, testis, muscle-skeletal, thyroid); GPANK1 (esophagus-mucosa, skin); 
Figure 1. Quantile–quantile plots of the expected and observed −log10(p-values) for the association of markers 
with FPG under additive (λ = 1.077) and recessive (λ = 1.047) models upon regular correction.
6Scientific RepoRtS |          (2020) 10:152  | https://doi.org/10.1038/s41598-019-57072-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
AIF1 (whole blood), C6orf25 (skin), SAPCD1-AS1 (skin); and TNXA (skin)]; the DHX58 marker regulates itself 
(in artery-tibial, adipose-subcutaneous, adipose-visceral, pancreas, and heart) and other genes such as KCNH4 
(esophagus-muscularis), HSPB9 (testis), and RAB5C (adipose-subcutaneous, pancreas, muscle-skeletal).
Associations between glucose-related traits and insulin resistance traits at the risk vari-
ants. Allelic association test statistics (Supplementary Table S4) for the identified risk variants in the third 
cohort of 283 samples considered for insulin resistance analysis indicated that the RPS6KA1, (VARS, VWA7), and 
CADPS markers passed the p-value threshold (<0.05) for associations with insulin resistance traits of HOMA-IR 
and HOMA-β and with the glucose-related traits of FPG and HbA1c; in addition, the association of the RPS6KA1 
marker with TG was replicated.
Results from multivariate analysis to examine relationships between glucose-related (FPG, HbA1C, TG) and 
insulin resistance (HOMA-IR, HOMA-β, C-peptide, HOMA-S) traits in the context of observed genotypes at risk 
variants (Table 8) indicated possible associations of the identified risk variants with insulin resistance:
 (I) RPS6KA1 marker: With genotypes homozygous for the risk allele, interactions between (TG, FPG and 
HbA1c) and insulin resistance traits (HOMA-β, C-peptide, HOMA-S) were observed at the multiple test-
ing significance threshold of <0.003. With the heterozygous genotype, TG was associated with HOMA-S at 
a p-value < 0.05.
 (II) [VARS, VWA7] marker: With genotypes that are heterozygous or homozygous for the risk allele, interac-
tions between FPG and insulin resistance traits (HOMA-β and HOMA-S) were observed at the multiple 
testing significance threshold of <0.003. With a heterozygous genotype, interactions between HbA1c 
and insulin resistance traits (HOMA-IR and HOMA-S) were observed at the multiple testing significance 
threshold of <0.003. TG also interacted with HOMA-S at a p-value = 0.007 with a heterozygous genotype.
SNP: Effect 
Allele: Trait
Gene: functional 
consequences Phase
Effect 
SizeR P-valueR
Effect 
SizeDM P-valueDM
rs1002487: C#, 
FPG RPS6KA1: intronic
Discovery 8.315 1.64E-08 8.297 1.58E-08
Replication 3.442 3.7E-04 3.509 2.15E-04
Meta 6.551 5.72E-11 6.652 2.89E-11
rs487321: A#, 
FPG CADPS: intronic
Discovery 6.133 1.53E-07 6.161 1.23E-07
Replication 3.955 2.25E-06 3.88 3.033E-06
Meta 7.047 1.83E-12 7.031 2.054E-12
rs707927: G@,$, 
FPG
VARS, VWA7: 
intron in VARS, 2 Kb 
upstream of VWA7
Discovery 0.9453 8.24E-06 0.9262 1.19E-05
Replication 0.6375 8.25E-05 0.6503 3.18E-05
Meta 5.928 3.074E-09 6.033 1.61E-09
rs12600570: 
T@, FPG DHX58: intronic
Discovery 0.8166 7.49E-06 0.8374 4.11E-06
Replication 0.3892 4.67E-03 0.3682 5.65E-03
Meta 5.142 2.715E-07 5.186 2.15E-07
The following associations with HbA1c are shown in this table for the sake of completion; HbA1c 
associations are not considered significant except in the case of RPS6KA1.
rs1002487: C#, 
HbA1C RPS6KA1: intronic
Discovery 7.367 4.91E-08 7.186 9.649E-08
Replication 1.811 2.71E-03 1.875 0.00115
Meta 5.784 7.27E-09 5.896 3.71E-09
rs487321: A#, 
HbA1C CADPS: intronic
Discovery 2.387 2.47E-03 2.38 2.44E-03
Replication 1.893 2.77E-04 1.826 3.82E-04
Meta 4.723 2.32E-06 4.569 3.18E-06
rs707927: G@, 
HbA1C
VARS, VWA7: 
intron in VARS, 2 Kb 
upstream of VWA7
Discovery 0.5632 5.43E-04 0.5502 6.96E-04
Replication 0.3689 1.63E-04 0.3799 8.33E-05
Meta 5.088 3.61E-07 5.181 2.21E-07
rs12600570: 
T@, HbA1C DHX58: intronic
Discovery 0.31 2.82E-02 0.3344 1.76E-02
Replication 0.194 1.98E-02 0.1805 2.81E-02
Meta 3.179 1.47E-03 3.178 1.48E-03
Table 3. List of the four identified risk variants associated with FPG either at genome-wide significant p-values 
(<1.8E-08) or at nominal p-values of 1.0 < E-06. EffectSize, Effect size represents beta value for discovery and 
replication phases, and Z-score for meta-analysis. R-regular correction: Corrected for age, sex and the top 
10 principal components that resulted from the Principal Components Analysis of the genotype data; DM: 
Corrected for diabetes medication in addition to the regular correction. #association with the trait was observed 
under the genetic model based on recessive mode of inheritance; @association with the trait was observed under 
the genetic model based on additive mode of inheritance. $Upon performing inverse normal transformation on 
the FPG values, the p-values for association of the marker rs707927 with FPG improved in the discovery phase; 
the values were (p-value = 1.26E-07; effect size = 0.3314) which upon further correction for diabetes medication 
were (p-value = 2.72E-07; effect size = 0.3226).
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 (III) CADPS marker: With a heterozygous genotype, associations between TG and HOMA-IR were observed 
at the multiple testing significance threshold of <0.003. Interaction between FPG and HOMA-β with a 
heterozygous genotype could be seen at a p-value < 0.003.
 (IV) DHX58 marker: With genotypes homozygous for the risk allele, TG and FPG were seen to be associated 
with (HOMA-IR and C-peptide levels) and HOMA-β, respectively, at the multiple testing significance 
threshold of <0.003. With heterozygous genotypes, FPG was associated with both HOMA-IR and HO-
MA-β at p-values < 0.05.
Discussion
This study identified a novel recessive marker (rs1002487) from RPS6KA1 (encoding Ribosomal Protein S6 
Kinase A1) associated with high FPG (and HbA1c) at genome-wide significance in native Kuwaiti people of 
Arab descent. S6K1 signaling has distinct roles in regulating glucose homeostasis in pro-opiomelanocortin and 
agouti-related protein neurons, key regulators of energy homeostasis25; and can potentially regulate insulin resist-
ance through phosphorylating insulin receptor substrate 1 (IRS-1)26. It participates in the NOTCH pathway, an 
effector of mTOR, and is sensitive to both insulin and certain nutrients. Our previous GWAS, using the same 
cohort12, demonstrated that the marker was also recessively associated with high TG at genome-wide signifi-
cance. FPG was directly correlated with TG and inversely correlated with HDL. Adiposity, high FPG, and TG are 
SNP: Effect Allele: 
Trait Gene Phase
Effect 
SizeBMI P-valueBMI
Effect 
SizeLM P-valueLM
Effect 
SizeDS P-valueDS
Effect Size 
DS+BMI+DM+LM P-valueDS+BMI+DM+LM
rs1002487: C#, FPG RPS6KA1: intronic
Discovery 8.416 1.02E-08 8.379 1.23E-08 6.388 1.53E-07 6.482 1.01E-07
Replication 3.355 2.62E-03 3.442 3.73E-04 3.492 2.16E-04 3.46 2.10E-04
Meta 6.233 4.58E-10 6.233 4.56E-10 6.357 2.05E-10 6.418 1.38E-10
rs487321: A#, FPG CADPS: intronic
Discovery 6.145 1.35E-07 6.177 1.22E-07 4.468 3.83E-06 4.48 3.61E-06
Replication 3.904 2.59E-06 3.979 2.06E-06 3.994 1.28E-08 4.00 8.97E-09
Meta 7.042 1.90E-12 7.089 1.35E-12 7.303 2.81E-13 7.356 1.88E-13
rs707927: G@,$, FPG
VARS, VWA7: 
intron in VARS, 2 Kb 
upstream of VWA7
Discovery 0.9289 1.14E-05 0.931 1.12E-05 0.658 1.73E-04 0.6523 2.01E-04
Replication 0.6446 6.29E-05 0.683 2.64E-05 0.614 6.59E-06 0.584 1.51E-05
Meta 5.926 3.11E-09 6.073 1.25E-09 5.851 4.87E-09 5.696 1.23E-08
rs12600570: T@, FPG DHX58: intronic
Discovery 0.7914 1.42E-05 0.831 5.19E-06 0.530 4.44E-04 0.5092 7.83E-04
Replication 0.3757 5.20E-03 0.391 3.88E-03 0.309 6.59E-03 0.291 9.74E-03
Meta 5.025 5.05E-07 5.238 1.62E-07 4.392 1.12E-05 4.191 2.78E-05
Table 4. Results from the analysis of correcting the observed associations for the additional covariates of 
obesity and diabetes status of the participants. #Association with the trait was observed under the genetic model 
based on recessive mode of inheritance; @association with the trait was observed under the genetic model based 
on additive mode of inheritance. EffectSizeEffect size represents beta value for discovery and replication phases, 
and Z-score for meta-analysis. RRegular correction - Corrected for age, sex and the top 10 principal components 
that resulted from the Principal Components Analysis of the genotype data; BMI,Corrected for BMI in addition 
to the regular correction; LMCorrected for lipid medication in addition to the regular correction; DSCorrected 
for diabetes status in addition to the regular correction; BMI+LM+DMCorrected for BMI and lipid & diabetes 
medications in addition to the regular correction.
SNP: Effect 
Allele: Trait Gene Phase
Effect 
SizeR P-valueR
Effect 
SizeBMI P-valueBMI
rs1002487: C#, 
FPG RPS6KA1: intronic
Discovery 8.371 7.63E-08 8.48 4.78E-08
Replication 3.378 1.27E-03 3.43 9.29E-04
Meta 4.895 9.85E-07 6.201 5.59E-10
rs487321: A#, 
FPG CADPS: intronic
Discovery 6.041 1.01E-06 6.055 8.94E-07
Replication 4.163 6.11E-06 4.092 7.35E-06
Meta 6.396 1.59E-10 6.645 3.04E-11
rs707927: 
G@,$, FPG
VARS, VWA7: 
intron in VARS, 
2 Kb upstream of 
VWA7
Discovery 1.011 6.34E-06 0.9928 8.93E-06
Replication 0.6265 4.49E-04 0.5916 8.38E-04
Meta 5.674 1.39E-08 5.502 3.75E-08
rs12600570: 
T@, FPG DHX58: intronic
Discovery 0.9928 8.93E-06 0.7241 1.7E-04
Replication 0.4363 3.30E-03 0.4233 4.1E-03
Meta 4.835 1.33E-06 4.803 1.56E-06
Table 5. Results from sensitivity analysis of preadjusting the FPG measurements by a fixed value (2.5 mmol/L) 
per diabetes medication status.
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hallmarks of insulin resistance27 and high FPG within the normoglycemic range can increase the risk for type 2 
diabetes28. The presented results indicate interactions between (TG, FPG, and HbA1c) and insulin resistance traits 
(HOMA-β, HOMA-S, C-peptide) at multiple testing significance with genotypes homozygous for the risk allele at 
the risk variant; even for the heterozygous genotype, TG was associated with HOMA-S (at p-value < 0.05). Thus, 
the present study, reporting for the first time that the RPS6KA1 marker is a risk variant for TG and glucose-related 
traits, is of considerable interest. Furthermore, in the GWAS catalog, the RPS6KA1 gene is associated with glucose 
homeostasis traits, sclerosis, and the symptom of rosacea. Reports have suggested that the rare homozygous (CC) 
state at the marker is involved in schizophrenia29. The GTeX resource annotates this marker as having the poten-
tial to regulate expression of the DHDDS gene, a locus associated with developmental delay and seizures (with 
or without movement abnormalities); patients with schizophrenia are also more prone to seizures. Patients with 
mental disorders, especially schizophrenia, are often afflicted by diabetes. Glucose homeostasis is altered upon the 
onset of schizophrenia, indicating that patients are at increased risk of diabetes30.
This study identified three further risk variants associated with FPG at nominal p-values of < 8.20E-06. These 
are rs487321 (recessive, intronic, CADPS), rs707927 (additive, intronic in VARS, and 2 Kb upstream of VWA7), 
and rs12600570 (additive, intronic, DHX58). Of these three suggestive markers, the CADPS and [VARS, VWA7] 
markers reached genome-wide significance (p-combined = 1.83E-12 and 3.07E-09, respectively) in meta-analysis 
that jointly analyzes the data from both the phases.
(i) CADPS encodes a calcium-dependent secretion activator involved in the exocytosis of vesicles filled with 
neurotransmitters and neuropeptides. Interestingly, the activator regulates the recruitment of insulin granules and 
SNP: Effect 
Allele: Trait
Gene: functional 
consequences Phase
Effect 
SizeR P-valueR
Effect 
SizeBMI+LM P-valueBMI+LM
Effect 
SizeBMI+LM+DM P-valueBMI+LM+DM
rs1002487: C#, 
FPG RPS6KA1: intronic
Discovery_diabetic 6.396 2.48E-04 6.487 2.11E-04 6.488 2.12E-04
Discovery_non- diabetic& NA NA NA NA
Replication_diabetic 17.83 4.74E-07 17.72 6.07E-07 17.7 6.50E-07
Replication_non- diabetic 0.0086 0.9886 −0.08115 0.8861
Meta_diabetic 6.011 1.84E-09 6.014 1.81E-09 6.004 1.93E-09
Meta_non-diabetic 0.014 0.9886 0.143 0.8861
Meta_all 4.173 3.0E-05 4.062 4.86E-05
rs487321: A#, 
FPG CADPS: intronic
Discovery_diabetic 5.781 3.1E-04 5.799 3.1E-04 5.797 3.1E-04
Discovery_non- diabetic −0.117 0.9872 0.1009 0.8885
Replication_diabetic 9.392 2.1E-04 9.346 2.36E-04 9.594 1.84E-04
Replication_non- diabetic 2.479 4.64E-08 2.429 1.07E-08
Meta_diabetic 5.132 2.86E-07 5.116 3.12E-07 5.154 2.55E-07
Meta_non-diabetic 4.190 2.78E-05 4.486 7.27E-06
Meta_all 6.420 1.36E-10 6.648 2.97E-11
rs707927: G@, 
FPG
VARS, VWA7: intron in 
VARS, 2 Kb upstream 
of VWA7
Discovery_diabetic 1.153 1.50E-03 1.157 1.51E-03 1.155 1.54E-03
Discovery_non- diabetic 0.1979 3.3E-02 0.1858 4.18E-02
Replication_diabetic 1.516 4.23E-04 1.518 4.35E-04 1.517 4.47E-04
Replication_non- diabetic 0.2364 1.1E-02 0.2011 2.04E-02
Meta_diabetic 4.683 2.83E-06 4.677 2.91E-06 4.668 3.05E-06
Meta_non-diabetic 3.327 8.78E-04 3.083 2.05E-03
Meta_all 5.458 4.82E-08 5.259 1.45E-07
rs12600570: 
T@, FPG DHX58: intronic
Discovery_diabetic 0.8421 8.46E-03 0.8328 9.55E-03 0.8303 9.85E-03
Discovery_non- diabetic 0.2308 3.35E-03 0.217 5.21E-03
Replication_diabetic 0.5816 0.101 0.5767 0.1052 0.5874 0.1002
Replication_non- diabetic 0.1955 1.2E-02 0.1955 1.17E-02
Meta_diabetic 3.080 2.07E-03 3.035 2.4E-03 3.042 2.35E-03
Meta_non-diabetic 3.814 1.30E-04 3.724 1.96E-04
Meta_all 4.898 9.71E-07 4.799 1.59E-06
Table 6. Results from the analysis of examining the identified associations in sub-cohorts of entirely diabetic 
patients or of entirely healthy participants. &In the case of the RPS6KA1 marker, all the individuals with 
genotype homozygous for risk allele were seen with the sub-cohort of Discovery_diabetic) and hence results 
for Discovery_ non-diabetic sub-cohort were unavailable. #Association with the trait was observed under the 
genetic model based on recessive mode of inheritance; @association with the trait was observed under the 
genetic model based on additive mode of inheritance. EffectSizeEffect size represents beta value for discovery 
and replication phases, and Z-score for meta-analysis. RRegular correction - Corrected for age, sex and the 
top 10 principal components that resulted from the Principal Components Analysis of the genotype data; 
BMI+LMCorrected for BMI and lipid medication in addition to the regular correction; BMI+LM+DMCorrected for 
BMI and lipid & diabetes medications in addition to the regular correction.
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Figure 2. Regional association plots showing the 4 identified risk variants (A) rs1002487, (B) rs487321, (C) 
rs707927, (D) rs12600570) and the markers in LD (from a 500 Kb genome region centered at the risk variants) 
with the risk variants in their respective gene regions and their association with FPG. The SNPs are color-coded 
as per the r2 value for the SNP with the identified risk variant (Blue dots: r2 ≤ 0.2; Purple dots: r2 > 0.2 & ≤ 0.4; 
Green dots: r2 > 0.4 & ≤ 0.6; Orange dots: r2 > 0.6 & ≤ 0.8; Red dots: r2 > 0.8 & ≤ 1.0). The X-axis represents 
the gene region in physical order; the Y-axis represents −log10 P-value of the associations with FPG for all the 
SNPs. The dashed horizontal line represents a p-value of 3.60E-08. To generate regional association plot for a 
SNP-trait association, all the genotyped SNPs (passing the quality control analyses) from a region of around 
500 Kb centered on the SNP were tested for association with the trait; the resultant statistics and the SNPs were 
displayed in the regional association plot. Region-plot tool (https://github.com/pgxcentre/region-plot) was used 
to produce regional plots.
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beta-cell function31,32; previous global GWAS associated CADPS loci with treatment interaction of sulfonylurea 
(a glucose-lowering drug) and heart failure-related metabolite levels21,22; and GTeX annotates the marker as reg-
ulating the expression of its own gene (CADPS) in adipose-subcutaneous and tibial artery tissues. Furthermore, 
as indicated in our results, with a heterozygous genotype at the risk variant, TG was significantly associated with 
HOMA-IR (p < 0.003) and FPG with HOMA-β (p < 0.003).
(ii) VARS encodes valyl-tRNA synthetase and is associated with diabetic cataract, neurodevelopmental disor-
der, microcephaly, seizures, and cortical atrophy. VWA7 encodes Von Willebrand Factor A Domain-Containing 
Protein 7; previous global GWAS associated the VWA7 locus with IBD, blood plasma proteome, blood protein 
levels, and schizophrenia. Furthermore, the risk variant and its 26 strong LD partners are from a gene-dense 
region, commonly referred to as the HLA “class III” region33, containing a large number of genes (i.e., TNF, 
AIF1, PRRC2A, APOM, BAG6, C6orf47, CSNK2B, GPANK1, LY6G5B, LY6G5C, ABHD16A, LOC105375018, 
LY6G6F-LY6G6D, LY6G6F, LY6G6E, LY6G6D, C6orf25, LY6G6C, MSH5-SAPCD1, MSH5, VARS, VWA7, 
C6orf48, NEU1, HSPA1A, EHMT2, and C2) (Fig. 2 and Supplementary Table S3). Markers and genes from the 
HLA region are associated with risk for type 1 diabetes34 and type 2 diabetes35: TNF mediates obesity-related 
insulin resistance36; the HSPA1A gene (encoding HSP70) gets upregulated and correlates with HbA1c levels in 
pregnant women with gestational diabetes37; people with type 2 diabetes have higher HSP70 levels in serum cor-
relating with diabetes duration38; and an upstream variant of HSPA1A (i.e., rs17201192, an LD partner (r2 = 0.83) 
of the reported [VARS, VWA7] marker) showed an association with FPG, albeit at a nominal p-value of 3.3E-05, 
in our analysis (see Supplementary Table S3). Our results imply, with genotypes of heterozygosity or homozygo-
sity for the risk allele, significant interactions between FPG and HOMA-β and HOMA-S; and with a heterozygous 
genotype, interactions between HbA1c and HOMA-IR and HOMA-S. TG was also seen to interact with HOMA-S 
at p = 0.007 with a heterozygous genotype. The [VARS, VWA7] variant appeared to regulate the expression of 
LY6G5B, GPANK1, AIF1, C6orf25, SAPCD1-AS1, and TNXA; previous global GWAS associated these genes with 
ASD and IBD, which are known to co-occur with type 2 diabetes39.
SNP
ROH group 
and the 
method used 
to identify 
the ROH@
Consensus 
ROH region
Distance to 
SNP from 
consensus 
ROH (in 
Mb)
Number of individuals 
from the discovery 
cohort (n = 1353) 
harboring the ROH 
(Distribution into sub-
cohort of participants 
diagnosed for T2DM 
(n = 605) versus sub-
cohort of non-diabetic 
participants (n = 748))
Length of 
consensus 
ROH (in Kb)
Count of SNPs 
in consensus 
ROH region
Mean ± SD of 
ROH groups
Distance to 
SNP from 
mean ± SD 
window (in 
Mb)
Presence of SNP 
in ROH regions 
identified in 
worldwide 
population 
(from 
Pemberton et 
al. study48)
rs1002487/RPS6KA1
S18181 1:28864435–29062427 1.99 51 (29:22) 197.99 11
24917436–
33009426 Overlapping
Yes
S15572 1:28056342–28084571 1.19 44 (27:17) 28.23 5
27723540–
28417372 0.85
rs487321/CADPS
S71771 3:62647115–63435226 0.143 29 (17:12) 788.11 226
3:55304385–
70777955 Overlapping
Yes
S71761 3:62315312–62315312 0.475 29 (16:13) 0.001 1
3:55748124–
68882499 Overlapping
S41142 3:61981197–62189189 0.60 31 (17:14) 207.99 85
3:56659352–
67511033 Overlapping
S41152 3:62604010–62604010 0.186 31 (16:15) 0.001 1
3:57340271–
67867749 Overlapping
S41162 3:62883050–63333375 0.0924 31 (18:13) 450.32 101
3:57761318–
68455106 Overlapping
S41172 3:63663215–63670140 6.93 31 (18:13) 0.873 3
3:58212832–
69120521 Overlapping
rs707927/[VARS, 
VWA7]
S17061 6:31001421–32989521 0.744 53 (29:24) 1988.10 1077
6:26827255–
36745549 Overlapping
No, But LD 
SNP rs805267 
(r2 = 0.69) is 
present
S6872 6:29569045–29593788 2.176 71 (38:33) 24.74 24
6:26617526–
32545306 Overlapping
S8242 6:31872383–32161430 0.126 64 (34:30) 289.05 126
6:29115193–
34918619 Overlapping
S10002 6:30112623–30125537 1.619 57 (30:27) 12.91 30
6:27129747–
33108413 Overlapping
S10012 6:31572927–31572927 0.173 57 (31:26) 0.001 1
6:28490667–
34655186 Overlapping
rs12600570/DHX58
S51531 17:39980819–40041676 Overlapping 34 (19:15) 60.858 8
17:36532212–
43490282 Overlapping
No, But LD 
SNP rs2074158 
(r2 = 0.56) is 
presentS17412
17:40041676–
40063083 0.219 43 (22:21) 21.408 5
17:39559717–
40545041 Overlapping
Table 7. ROH regions overlaying the identified risk variants. @Two approaches were used to identify ROH segments 
(see Methods for details). Method 1: Markers that passed quality control were pruned for LD (r2 > 0.9) (n = 568,670) 
and employed to detect ROH segments using parameters suggested by Howrigan et al.52; Method 2: Un-pruned 
marker set (n = 632,375) was employed to detect ROH using parameters deployed in Christofidou et al.53.
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Interaction Effect Size Std. Error P-value@
Recessive Marker rs1002487-C/RPS6KA1
Model: TG~rs1002487* insulin resistance traits
   CC: HOMA-IR 11.78 4.12 0.0047
   TC: HOMA-IR 12.95 7.17 0.072
   CC: HOMA-β −4.31 0.69 1.5E-09
   TC: HOMA-β 0.078 0.17 0.655
   CC: C-peptide 1959.1 292.95 1.25E-10
   TC: C-peptide 26.11 18.32 0.152
   CC: HOMA-S −2.633 0.418 1.16E-09
   TC: HOMA-S −0.299 0.145 0.0397
Model: FPG~rs1002487* insulin resistance traits
   CC: HOMA-IR 0.209 0.308 0.497
   TC: HOMA-IR −0.394 0.537 0.463
   CC: HOMA-β −0.247 0.043 3.62E-08
   TC: HOMA-β 0.0013 0.011 0.900
   CC: C-peptide 122.2 5.046 8.19E-07
   TC: C-peptide 0.682 1.515 0.653
   CC: HOMA-S −0.162 0.032 1.25E-06
   TC: HOMA-S −0.0005 0.011 0.995
Model: HbA1C~rs1002487* insulin resistance traits
   CC: HOMA-IR 0.341 0.201 0.090
   CT: HOMA-IR −0.624 0.349 0.075
   CC: HOMA-β −0.138 0.029 3.04E-06
   CT: HOMA-β −0.0008 0.007 0.257
   CC: C-peptide 66.96 14.77 8.73E-06
   CT: C-peptide −0.886 0.924 0.338
   CC: HOMA-S −0.092 0.02 1.35E-05
   CT: HOMA-S 0.0037 0.007 0.606
Additive Marker rs707927-G/[VARS, VWA7]
Model: TG~rs707927* insulin resistance trait
   AG: HOMA-IR 9.845 3.351 0.0035
   GG: HOMA-IR 17.318 78.544 0.825
   AG: HOMA-β −0.307 0.165 0.064
   GG: HOMA-β −0.435 0.817 0.595
   AG: C-peptide 8.396 17.182 0.625
   GG: C-peptide −139.584 258.03 0.588
   AG: HOMA-S −0.313 0.116 0.007
   GG: HOMA-S 0.009 0.521 0.986
Model: FPG~rs707927* insulin resistance trait
   AG: HOMA-IR 0.239 0.233 0.306
   GG: HOMA-IR 24.48 5.470 1.11E-05
   AG: HOMA-β −0.034 0.009 0.00032
   GG: HOMA-β −0.194 0.047 5.17E-05
   AG: C-peptide 0.100 1.272 0.937
   GG: C-peptide −77.43 19.10 6.59E-05
   AG: HOMA-S −0.020 0.008 0.012
   GG: HOMA-S −0.140 0.037 0.00019
Model: HbA1C~rs707927* insulin resistance trait
   AG: HOMA-IR 0.482 0.159 0.0024
   GG: HOMA-IR 7.012 3.736 0.0615
   AG: HOMA-β −0.021 0.006 0.0013
   GG: HOMA-β −0.048 0.032 0.127
   AG: C-peptide 0.827 0.788 0.295
   GG: C-peptide −22.07 11.84 0.063
   AG: HOMA-S −0.018 0.005 0.0005
   GG: HOMA-S −0.043 0.023 0.0686
Recessive Marker rs487321-A/CADPS
Continued
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Interaction Effect Size Std. Error P-value@
Model: TG~rs487321* insulin resistance trait
   GA: HOMA-IR −17.71 6.001 0.003
   AA: HOMA-IR NA NA NA
   GA: HOMA-β 0.091 0.186 0.623
   AA: HOMA-β NA NA NA
   GA: C-peptide −0.661 18.710 0.972
   AA: C-peptide NA NA NA
   GA: HOMA-S 0.109 0.150 0.468
   AA: HOMA-S NA NA NA
Model: FPG~rs487321* insulin resistance trait
   GA: HOMA-IR −0.316 0.446 0.476
   AA: HOMA-IR NA NA NA
   GA: HOMA-β −0.024 0.011 0.032
   AA: HOMA-β NA NA NA
   GA: C-peptide −1.55 1.464 0.288
   AA: C-peptide NA NA NA
   GA: HOMA-S 0.0006 0.011 0.952
   AA: HOMA-S NA NA NA
Model: HbA1C~rs487321* insulin resistance trait
   GA: HOMA-IR 0.038 0.294 0.896
   AA: HOMA-IR NA NA NA
   GA: HOMA-β −0.007 0.007 0.330
   AA: HOMA-β NA NA NA
   GA: C-peptide 0.088 0.881 0.920
   AA: C-peptide NA NA NA
   GA: HOMA-S −0.0041 0.007 0.5610
   AA: HOMA-S NA NA NA
Additive Marker rs12600570-T/DHX58
Model: TG~rs12600570* insulin resistance trait
   CT: HOMA-IR −7.86 5.063 0.122
   TT: HOMA-IR 59.60 17.11 0.00057
   CT: HOMA-β 0.116 0.128 0.3654
   TT: HOMA-β 0.667 0.490 0.1742
   CT: C-peptide 3.11 17.42 0.858
   TT: C-peptide 178.71 44.06 6.50E-05
   CT: HOMA-S 0.155 0.093 0.095
   TT: HOMA-S −0.971 0.393 0.014
Model: FPG~rs12600570* insulin resistance trait
   CT: HOMA-IR 1.005 0.375 0.0078
   TT: HOMA-IR 2.797 1.268 0.0282
   CT: HOMA-β −0.018 0.0076 0.0158
   TT: HOMA-β −0.135 0.0291 5.09E-06
   CT: C-peptide −0.781 1.391 0.574
   TT: C-peptide −10.22 3.517 0.0039
   CT: HOMA-S −0.004 0.007 -0.660
   TT: HOMA-S −0.081 0.029 -2.712
Model: HbA1C~rs12600570* insulin resistance trait
   CT: HOMA-IR 0.213 0.254 0.402
   TT: HOMA-IR 0.153 0.859 0.858
   CT: HOMA-β 0.002 0.0052 0.601
   TT: HOMA-β −0.012 0.0196 0.531
   CT: C-peptide −0.363 0.848 0.668
   TT: C-peptide −1.861 2.144 0.386
   CT: HOMA-S 0.0015 0.004 0.720
   TT: HOMA-S −0.0176 0.0188 0.350
Table 8. Interactions between (TG, FPG, HbA1c) and Insulin Resistance traits (HOMA-IR, HOMA-β, 
C-peptide, HOMA-S) with respect to genotypes at the risk variants. @Multiple testing significance threshold for 
p-value is 0.003. All the interaction models were corrected for age and gender.
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(iii) The DHX58 gene encodes DExH-box helicase 58. Previous global GWA studies associated a missense 
variant (i.e., rs2074158-T/DHX58), which is in LD (r2 = 0.56) with the reported DHX58 risk variant, with 
CAD (p-value = 2.0E-10) in UK BioBank populations17. We further noticed that the identified ROH region 
(17:36532212–43490282) (see Table 7) covering the DHX58 marker overlaps with the ROH (17: 36839131–
38938944) (see Table 4 from our previous publication12) covering a marker (rs9972882 from PGAP3) that is 
associated with high triglyceride levels12.
The presented results indicate that the DHX58 risk variant regulates DHX58, RAB5C, KCNH4, and HSPB9; 
interestingly, previous global GWAS implicated these four genes in CAD17. Furthermore, markers from RAB5C 
were associated with fibrinogen levels, which are known to be elevated in diabetic patients, especially those with 
foot ulcers40. Our results pointed to significant (p-value < 0.003) interactions between TG and (HOMA-IR and 
C-peptide levels) and between FPG and HOMA-β at genotypes homozygous for a risk allele.
All the four identified risk variants are intronic; however, as discussed above, genotype-tissue expression data 
revealed that each of the four variants can regulate genes that are associated with diabetes-related or comorbid 
disorders. Given that a large burden of homozygosity and excess of recessive alleles are attributed to Arab popu-
lation from Kuwait8, the observations that two of the four identified risk variants appeared when genetic model 
based on the recessive mode of inheritance was used and that all four variants were in ROH segments are not 
surprising.
Association tests were examined with both raw and inverse normal transformed FPG values. The reported 
four associations remained significant when co-variate adjustments were done for diabetes medication, obe-
sity and diagnosis for diabetes. The four associations remained significant when FPG values were preadjusted 
by a fixed amount per diabetes medication status. Further examination of the identified associations in the 
sub-cohorts of entirely diabetic patients or of entirely healthy participants revealed that the RPS6KA1, CADPS 
and VARS markers performed better in terms of retaining significance in cohorts of diabetic patients and the 
DHX58 marker in the cohort of participants free of diabetes.
Consideration of ethnic populations in association studies is supposed to help in enlarging the global catalog 
of risk loci by way of indicating novel risk loci (not seen in major continental populations). Previous studies from 
the region on Arab cohorts demonstrated this aspect by way of identifying novel risk loci for type 2 diabetes 
(T2DM) at either genome-wide significant or suggestive p-values for associations – such loci include KIF12, 
DVL1, EPB41L3, DTNB, DLL1, CTNNB1, JAG1, MLXIP, CDKLAL1, TCF7L2, KCTD8, GABRG1, GABRA2, 
COX7B2, GABRA4, ZNF106 and OTX2-AS1 (Supplementary Table S5)41–45. Our study now adds RPS6KA1, 
CADPS, (VARS, VWA7), and DHX58 to this list of novel T2DM risk loci in Arab population.
Because of the nature of the study design that uses HumanOmniExpress BeadChip, the study does not con-
sider genetic variants that are seen only in the Arab population. However, we find that there are statistically 
significant differences in genotype distributions at the risk variants between the Arab population and continental 
populations (Supplementary Table S6). The risk allele frequencies also differ substantially across the populations 
(Supplementary Figure S5). In order to identify Arab-population-specific risk variants (that are not polymor-
phic in continental population), we need to perform large-scale genome-wide surveys (a combination of GWAS, 
exome, and genome sequencing and imputation) of the Arab population with diabetes46.
Our earlier studies identified three population subgroups in Kuwait8. the first group (Kuwait P) is largely 
of West Asian ancestry, representing Persians with European admixture; the second group (Kuwait S) is pre-
dominantly of city-dwelling Saudi Arabian tribe ancestry, and the third group (Kuwait B) includes most of the 
tent-dwelling Bedouin and is characterized by the presence of 17% African ancestry. Allele frequency assessment 
of the identified 4 risk variants among these substructures (Fig. 3) suggests that the variant rs1002487/RPS6KA1 
is enriched in Persian ancestry, rs12600570/DHX58 in nomadic Bedouin ancestry, rs707927/(VARS, VWA7) in 
Saudi Arabian ancestry followed by nomadic Bedouin ancestry while the frequency of rs487321/CADPS is almost 
equal among the three population substructures of Kuwait.
Limitations of the study include the following: (i) Among study cohorts, there are many subjects assuming 
hypoglycemic therapy – which we took care by way of adjusting the association tests for medication and by 
performing sensitivity analysis; however, the such individuals at risk for hyperglycemia might have introduced 
corrective actions (such as exercise, hypocaloric diet and food supplements) affecting FPG; unfortunately, data 
relating to these corrective measures were not available and hence we were unable to consider them in associa-
tion test models or in sensitivity analysis. (ii) The study cohort is relatively small, a limitation which might have 
hindered the ability to identify more than just the four reported risk variants and to observe any of the established 
risk variants for glucose-related traits. There is an urgent need to carry out much larger studies on the genetics of 
diabetes in Arab populations which are notorious for high prevalence of obesity and diabetes46.
Conclusions
This study identified novel risk variants for high FPG in the Arab population of Kuwait. The RPS6KA1 gene 
(associated with FPG at genome-wide significance) is known to be involved in glucose homeostasis. Gene loci of 
CADPS, (VARS, VWA7), and DHX58 exhibiting nominal associations with FPG were often found to be associ-
ated with CAD in previous global GWAS. The identified four associations remained significant when the regres-
sion models were adjusted for various confounders (such as medication, obesity and diabetes status) and when 
the FPG levels were preadjusted by a fixed value per diabetes medication status. The RPS6KA1, CADPS and 
VARS markers performed better in terms of retaining significance in cohorts of entirely diabetic patients and 
the DHX58 marker in the cohort of participants free of diabetes. With heterozygous or homozygous risk allele 
genotypes at these risk variants, significant interactions appear to occur between glucose-related and insulin 
resistance traits. The identified gene loci were previously associated with various other disorders (including IBD, 
schizophrenia, and autism) that appear to share risk factors with diabetes. This study presents, for the first time, 
potential associations between the RPS6KA1 gene loci and high TG, FPG, and HbA1c.
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Methods
Ethics approval and consent to participate. This study was reviewed and approved by the institutional 
Ethical Review Committee at Dasman Diabetes Institute, Kuwait. Participant recruitment and blood sample col-
lection were conducted under protocols adopted by the Ethical Review Committee. Signed informed consent was 
obtained from each participant.
Study participants. Details on participant recruitment and a description of the study cohorts are presented 
in our previous paper12 (for details, see Supplementary Material: Methods section on Study participants). Briefly, 
3,145 participants were recruited from two cohorts in Kuwait. A representative sample of Kuwaiti native adults 
randomly selected from each of the six governorates of Kuwait formed the first group. Native Kuwaitis visiting our 
institutional clinics for tertiary medical care or our campaigns formed the second group; such visitors interested 
in participating were invited later to give blood samples after overnight fasting. We confirmed ethnicity through 
detailed questioning on parental lineage up to three generations. Data on age, sex, medical history, and medica-
tion were also recorded, as were baseline characteristics and vital signs. The discovery cohort was drawn largely 
from the second group and the replication cohort from the first group. 1,913 of the recruited participants were 
used for the discovery phase and 1,176 for the replication phase.
Power calculation. We adopted the “gene only” hypothesis and performed two types of power calculation 
(for details, see Supplementary Material: Methods section on Power calculation): (Type i): Quanto47 was imple-
mented to evaluate sample size and the potential to detect FPG trait variance with 80% power and p-value < 5.0E-
08. Marginal genetic effect estimates (RG2) were made to increment from 0.001 to 0.04 in steps of 0.001 in order 
to detect genetic effects explaining at least 0.1%–4% of trait variance could be detected. (Type ii): QPowR (https://
msu.edu/~steibelj/JP_files/QpowR.html) was used to determine the sample size for achieving 80% power for the 
study design of two phases (discovery and replication) with total sample size of 2,529, total heritability of 0.05, 
samples genotyped each of the two phases as ~50% of 2,529, markers typed in the second phase as ~0.2% of the 
markers typed in the first phase, and type I error rate of 5.0E-08.
Genotyping in the discovery and replication phases. Genome-wide genotyping was performed on 
an Illumina HumanOmniExpress Array. Top associating markers in the discovery phase were genotyped in rep-
lication phase using TaqMan® SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) and ABI 
7500 Real-Time PCR System (Applied Biosystems) (for details, see Supplementary Material: Methods section on 
Sample processing: Discovery phase and Replication phase).
Quality control analyses. Raw intensity data from all samples were pooled and genotype calling was per-
formed using GenomeStudio software. A series of quality metric thresholds was applied to derive a high-quality 
set of SNPs and samples (for details, see Supplementary Material: Methods section on Quality control analysis). 
Samples with a call rate >95% were retained. SNPs with inappropriate call quality were removed. Sex was esti-
mated using GenomeStudio and removed mismatched samples. Strand designations were corrected to the for-
ward strand, and REF/ALT designations were corrected using the design files for HumanOmniExpress BeadChip. 
Markers with allele frequency (–maf 0.01), and deviation from Hardy–Weinberg equilibrium (HWE <10−6) were 
removed. We derived a set of LD-pruned markers (n = 340,299) by removing markers in LD (r2 > 0.5) with oth-
ers in a sliding window of 50-SNP and the LD-pruned marker set was used to measure relatedness among par-
ticipants to the extent of third-degree relatives, to perform ancestry estimation (using ADMIXTURE48), and 
Figure 3. Assessment of allele frequencies at the identified 4 risk variants among the three population 
substructures of Kuwait. Saudi: Kuwait S subgroup that is predominantly of city-dwelling Saudi Arabian tribe 
ancestry; Persian: Kuwait P subgroup that is largely of West Asian ancestry, representing Persians; Bedouin: 
Kuwait B subgroup that is of tent-dwelling Bedouin ancestry46.
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principal component analysis (using EIGENSTRAT49). One sample per pair of related participants was randomly 
removed. Samples with abnormal deviations, in the extents of component ancestry elements, from what we had 
established for the three Kuwaiti population subgroups8 were removed as samples of ethnicity mismatch. Outliers 
in PCA were identified and the corresponding samples were removed.
Quantitative trait association tests. In discovery phase, all the 632,375 SNPs that passed quality control 
were used in association tests. Selected markers from discovery phase were tested in the replication phase. Both 
the additive and recessive genetic models were used in tests for associations with FPG and HbA1c. Two types of 
corrections were made to the associations tests – “Regular Corrections” involved adjustments for age, sex, and the 
first 10 principal components; and “Additional Corrections” involved further adjustment for glucose-lowering 
medication.
Joint analysis with results from discovery and replication phases. The METAL tool50 was used to 
perform meta-analysis with association test statistics from both the discovery and replication phases. Combined 
analysis of data from both the phases is believed to enable detecting genetic associations with increased power51.
P-value thresholds to assess significance of associations. Threshold for genome-wide significant 
p-values were calibrated for the counts of LD-pruned markers (n = 340,299), quantitative traits (n = 2, FPG and 
HbA1c), genetic models (n = 2, additive or recessive), and correction models for the association tests (n = 2, 
regular correction and further correction for glucose-lowering medication). The “stringent” p-value threshold 
to keep the type I error rate at 5% got calibrated to 1.84E-08. We further defined a “nominal” p-value threshold 
of (>1.84E-08 and <E-05) to identify “suggestive” associations. P-value threshold for significant associations in 
replication phase was set at 0.05.
Identifying runs of homozygosity (ROH). Runs of Homozygosity (ROH) were identified, using PLINK-
1.9, through two approaches: (Approach-1): Markers that passed quality control were pruned for LD (r2 > 0.9) 
(n = 568,670) and employed to detect ROH segments using parameters recommended by Howrigan et al.52 
(Approach-2): The unpruned marker set (n = 632,375) was employed and parameters deployed by Christofidou 
et al.53 were used. Consensus ROH regions were derived for the identified groups of overlapping ROH segments 
and mean ± SD was calculated (by considering the midpoint of each individual ROH falling in the group). 
Delineated ROH segments were classified as “known” or “novel” by comparison with ROH signatures discovered 
in global populations54.
Derivation of insulin resistance traits and association with glucose-related traits. We consid-
ered a subset of 283 samples, randomly selected from the replication cohort, and measured C-peptide levels 
in plasma (for details, see Supplementary Material: Methods section on Derivation of insulin resistance traits). 
Insulin resistance traits (i.e., HOMA-IR, HOMA-β, and HOMA-S) were calculated using the FPG (mmol/l) and 
C-peptide (nmol/l) values with the HOMA2 calculator (https://www.dtu.ox.ac.uk/homacalculator/). Multivariate 
linear regression, corrected for age and sex, was performed to assess interactions between (TG, FPG, HbA1c) 
and insulin resistance traits with respect to the genotypes at risk variants; standardized beta-coefficients (β1) 
and test significance (p-values) were derived using the R Project for Statistical Computing software (https://
www.r-project.org/). The p-value threshold calibrated for multiple testing was 0.003 (=0.05/16); the denominator 
corresponds to four interaction models on each of the four risk variants.
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